Primary Sclerosing Cholangitis (PSC) Market to Nearly Double, Reaching USD 363.9 Million by 2035, Driven by Rising R&D and Therapeutic Advancements

The global Primary Sclerosing Cholangitis (PSC) Market is projected to experience robust growth over the next decade, expanding from an estimated USD 174.9 million in 2025 to USD 363.9 million by 2035, reflecting a compound annual growth rate (CAGR) of 7.6%, according to a recent market analysis by Future Market Insights.

This trajectory underscores the expanding recognition of PSC as a serious unmet medical condition and reflects increasing clinical research activity, regulatory incentives, and a strong pipeline of innovative therapies.

Key Market Highlights

Market Value 2025: USD 174.9 million
Forecast 2035: USD 363.9 million
CAGR (2025-2035): 7.6%
Leading Segment (2025): BTT1023 (18.5% market share)
Top Growth Regions: North America, Asia-Pacific, Europe
Major Players: Intercept Pharmaceuticals, Gilead Sciences, Takeda, Allergan, Falk Pharma, NGM Biopharmaceuticals, Sirnaomics

Click Here for More Information:- https://www.futuremarketinsights.com/reports/primary-sclerosing-cholangitis-psc-market

Market Growth Drivers

The PSC market is benefitting from several critical trends reshaping the rare disease and hepatology landscape:

Rising Prevalence of PSC and Related Conditions
PSC remains a leading cause of liver transplantation in the U.S., with strong associations to inflammatory bowel disease and hepatobiliary cancers. Recent studies indicate an incidence of 0.4-0.7 cases per 100,000 in the UK and prevalence as high as 16.2 per 100,000 in some regions, highlighting the urgency for therapeutic interventions.
Unmet Medical Need Driving Drug Innovation
Current treatment relies heavily on liver transplantation, a costly procedure exceeding USD 577,000 in the U.S. with significant recurrence risks. Pharmaceutical innovators are targeting safer, more effective drug-based therapies that address inflammation and fibrosis, creating new opportunities for growth.
Regulatory Incentives and Orphan Drug Designations
Regulatory agencies are accelerating PSC research through orphan drug pathways and fast-track designations. This has catalyzed biotech collaborations and increased investor confidence.
Competitive Landscape and Benchmarking

The PSC market is increasingly competitive, with established players and start-ups intensifying R&D activity:

BTT1023 leads with an anticipated 18.5% share by 2025, supported by favorable clinical trial outcomes and a differentiated mechanism targeting vascular adhesion protein 1.
Gilead Sciences and Intercept Pharmaceuticals remain influential, leveraging their existing expertise in liver and metabolic diseases to strengthen their PSC pipelines.
Sirnaomics is pioneering RNA-based therapeutics with its STP707 candidate, which entered Phase I clinical trials in 2025.
Engitix secured €48M in Series A funding to advance tissue model-based PSC drug discovery, signaling strong investor interest in novel therapeutic platforms.
This wave of investment mirrors broader biotech trends, where companies are rapidly advancing therapies for rare diseases, mirroring strategies used in conditions such as Primary Biliary Cholangitis (PBC) and NASH (Nonalcoholic Steatohepatitis).

Regional Insights

North America: Projected to hold 42% market share in 2025, driven by advanced healthcare infrastructure, strong reimbursement systems, and heightened R&D activity. The U.S. remains a key hub for PSC clinical trials.
Asia Pacific: Expected to expand at the fastest CAGR (7.4%), supported by medical tourism growth, rising liver disease prevalence, and expanding healthcare access in countries such as China and India.
Europe: Sustains steady growth with increased incidence rates in Northern Europe and strong regulatory support for orphan disease treatments.
Challenges and Constraints

Despite strong momentum, several barriers may limit PSC market expansion:

High cost of drug development, with many therapies failing in late-stage trials.
Regulatory complexities, particularly in rare disease drug approvals, prolong commercialization timelines.
Limited patient recruitment in clinical trials due to the disease's rarity, restricting evidence generation for new therapies.
These factors highlight the need for global collaboration, patient-centric trial designs, and investments in real-world evidence collection.

Start-up Ecosystem Fueling Innovation

A growing number of start-ups are entering the PSC space with disruptive technologies:

Hepagene is developing HPG1860 for PSC, alongside candidates for NASH and HBV.
Qing Bile Therapeutics is advancing bile acid-based therapeutics, exploring tetrahydroxylated bile acids (THBAs) as a novel treatment approach.
PBC (founded 2014) offers digital health solutions, including a mobile app for tracking liver markers, reflecting the rising role of patient-centered care.

Get Sample Report: - https://www.futuremarketinsights.com/reports/sample/rep-gb-16176

Future Outlook

With PSC prevalence rising, clinical trial pipelines expanding, and increasing regulatory incentives, the market outlook remains optimistic. The focus is shifting toward disease-modifying therapies that could alter PSC's natural progression, a step beyond symptom management.

According to Future Market Insights, the PSC market is positioned to become a benchmark for orphan disease drug development, paralleling advancements seen in other hepatology indications.

Therapy Area Industry Analysis Reports:-

Adrenogenital Syndrome Treatment Market
https://www.futuremarketinsights.com/reports/adrenogenital-syndrome-treatment-market

Abetalipoproteinemia Management Market
https://www.futuremarketinsights.com/reports/abetalipoproteinemia-management-market

Weight Loss and Obesity Management Market
https://www.futuremarketinsights.com/reports/weight-loss-and-obesity-management-market

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analystsworldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

This release was published on openPR.